Pharmacological synergy: The next frontier on therapeutic advancement for migraine

Headache

Volumn 52, Issue 4, 2012, Pages 636-647

  Blumenfeld, Andrew ^a   Gennings, Chris ^b   Cady, Roger ^c  

^a Headache Center of Southern California   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c HEADACHE CARE CENTER   (United States)

Author keywords

migraine; naproxen sodium; sumatriptan; synergy

Indexed keywords

NAPROXEN; PLACEBO; SUMATRIPTAN;

DRUG RESPONSE; FOLLOW UP; HUMAN; MIGRAINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE INHIBITORS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MIGRAINE DISORDERS; NAPROXEN; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SUMATRIPTAN; TRYPTAMINES; WORLD HEALTH ORGANIZATION;

EID: 84859703134     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.02058.x     Document Type: Review

References (44)

1. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H,. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991; 265: 2831-2835.
2. The Subcutaneous Sumatriptan International Study Group. Subcutaneous sumatriptan in the acute treatment of migraine. N Engl J Med. 1991; 325: 316-321.
3. Bigal ME, Bordini CA, Antoniazzi AL, Special JG,. The triptan formulations: A critical evaluation. Arq Neuropsiquiatr. 2003; 61: 313-320.
4. Garcia-Ramos G, MacGregor EA, Hilliard B, Bordini CA, Leston J, Hettiarachchi J,. Comparative efficacy of eletriptan vs naratriptan in the acute treatment of migraine. Cephalalgia. 2003; 23: 869-876.
5. Cady R, Martin V, Mauskop A, et al,. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache. 2006; 46: 914-924.
6. Tfelt-Hansen P,. Triptans vs other drugs for acute migraine. Are there differences in efficacy? A comment. Headache. 2008; 48: 601-605.
7. Rothrock JF,. Opiate and opioid ("narcotic") therapy for acute migraine headache. Headache. 2010; 50: 1255-1256.
8. Hoffert MJ, Couch JR, Diamond S, et al,. Transnasal butorphanol in the treatment of acute migraine. Headache. 1995; 35: 65-69.
9. Goldstein J, Gawel MJ, Winner P, et al,. Comparison of butorphanol nasal spray and fiorinal with codeine in the treatment of migraine. Headache. 1998; 38: 516-522.
10. Kelly AM, Walcynski T, Gunn B,. The relative efficacy of phenothiazines for the treatment of acute migraine: A meta-analysis. Headache. 2009; 49: 1324-1332.
11. Freitag FG,. Divalproex in the treatment of migraine. Psychopharmacol Bull. 2003; 37 (Suppl. 2): 98-115.
12. Hurtado TR, Vinson DR, Vandenberg JT,. ED treatment of migraine headache: Factors influencing pharmacotherapeutic choices. Headache. 2007; 47: 1134-1143.
13. Smith TR, Sunshine A, Stark SR, et al,. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005; 45: 983-991.
14. GlaxoSmithKline news release, April 16, 2008, Treximet (sumatriptan and naproxen sodium) tablets approved by FDA for acute treatment of migraine.
15. Goadsby PJ, Ramadan NM,. Potential new drugs for acute and prophylactic treatment of migraines. In:, Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches. 4th edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2006: 569-576.
16. Welch KM,. Drug therapy of migraine. N Engl J Med. 1993; 329: 1476-1483.
17. Moskowitz MA,. The neurobiology of vascular head pain. Ann Neurol. 1984; 16: 157-168.
18. Ahn AH, Basbaum AI,. Tissue injury regulates serotonin 1D receptor expression: Implications for the control of migraine and inflammatory pain. J Neurosci. 2006; 26: 8332-8338.
19. Duggan KC, Walters MJ, Musee J, et al,. Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. J Biol Chem. 2010; 285: 34950-34959.
20. Welch KM,. The therapeutics of migraine. Curr Opin Neurol Neurosurg. 1993; 6: 264-269.
21. Haberer LJ, Walls CM, Lener SE, Taylor DR, McDonald SA,. Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2010; 50: 357-373.
22. Brandes JL, Kudrow D, Stark SR, et al,. Sumatriptan-naproxen for acute treatment of migraine. JAMA. 2007; 297: 1443-1454.
23. Fleiss JL,. The Design and Analysis of Clinical Experiments. New York, NY: John Wiley & Sons; 1999: 96-103.
24. Berenbaum MC,. What is synergy? Pharmacol Rev. 1989; 41: 93-141.
25. Holt MA, Stamey JD, Seaman JW, Young DM,. A note on tests for interaction in quantal response data. J Stat Comput Simul. 2004; 74: 683-690.
26. Piegorsch WW, Weinberg CR, Haseman JK,. Testing for simple independent action between two factors for dichotomous response data. Biometrics. 1986; 42: 413-419.
27. Finney DJ,. Probit Analysis. 3rd edn. Cambridge, UK: Cambridge University Press; 1971: 136-146.
28. Carter WH, Gennings C, Staniswalis JG, et al,. A statistical approach to the construction and analysis of Isobolograms. J Am Coll Toxicol. 1988; 7: 963-973.
29. Berenbaum MC,. The expected effect of a combination of agents: The general solution. J Theor Biol. 1985; 114: 413-431.
30. Gennings C, Carter WH Jr, Carchman RA, Teuschler LK, Simmons JE, Carney EW,. A unifying concept for assessing toxicological interactions: Changes in slope. Toxicol Sci. 2005; 88: 287-297.
31. US EPA. 2000) Supplementary guidance for conducting health risk assessment for chemical mixtures.
32. Vandenhende F, Lambert P, Ramadan N,. Statistical models for the analysis of controlled trials on acute migraine. Pharm Stat. 2003; 2: 199-210.
33. Milton SJ,. Statistical Methods in the Biological and Health Sciences. Boston, MA: McGraw Hill; 1998: 242-245.
34. Dowson A,. Can oral 311C90, a novel 5-HT1D agonist, prevent migraine headache when taken during an aura? Eur J Neurol. 1996; 36 (Suppl. 2): 28-31.
35. Olesen J, Diener HC, Schoenen J, Hettiarachchi J,. No effect of electriptan administration during the aura phase of migraine. Eur J Neurol. 2004; 11: 671-677.
36. Bates D, Ashford E, Dawson R, et al,. Subcutaneous sumatriptan during the migraine aura (Sumatriptan Aura Study Group). Neurology. 1994; 44: 1587-1592.
37. Aurora SK, Barrodale PM, McDonald SA, Jakubowski M, Burstein R,. Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine. Headache. 2009; 49: 1001-1004.
38. Rodgers AJ, Hustad CM, Cady RK, et al,. Total migraine freedom, a potential primary endpoint to assess acute treatment in migraine: Comparison to the current FDA requirement using the complete rizatriptan study database. Headache. 2011; 51: 356-368.
39. Cady RK, Lipton RB, Hall C, Stewart WF, O'Quinn S, Gutterman D,. Treatment of mild headache in disabled migraine sufferers: Results of the Spectrum Study. Headache. 2000; 40: 792-797.
40. Goadsby PJ,. The "Act when Mild" (AwM) study: A step forward in our understanding of early treatment in acute migraine. Cephalalgia. 2008; 28 (Suppl. 2): 36-41.
41. Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R,. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache. 2005; 45: 850-861.
42. Chobanian AV, Bakris GL, Black HR, et al, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA. 2003; 289: 2560-2572.
43. Bliss CI,. The toxicity of poisons applied jointly. Ann Appl Biol. 1939; 26: 585-615.
44. Wahrendorf J, Zentgraf R, Brown CC,. Optimal design for the analysis of interactive effects of two carcinogens or other toxicants. Biometrics. 1981; 37: 45-54.